Drug Profile
Research programme: pulmonary hypertension therapeutic - Vectura/University of Giessen
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Activaero GmbH
- Developer Justus Liebig University Giessen; Vectura
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pulmonary hypertension
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pulmonary-hypertension in Germany (Inhalation)
- 13 Mar 2014 Activaero GmbH has been acquired by Vectura
- 23 Apr 2013 Preclinical trials in Pulmonary hypertension in Germany (Inhalation) prior to April 2013